HNGE · Hinge Health, Inc.
$97.94
+0.70 (+0.72%)
At close · Oct 1
Return incl. dividend (before tax)
Market Cap
$7.71B
Shares
80.69M
Volume · Oct 1
1.42M
Avg daily vol (3M)
1.78M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$97.94
Open$97.00
Day$96.33–98.46
52W close$31.17–97.94
Avg vol 30d1.9M
Short int4.8M · 6.0% float · 2.7d
Short vol54%
Last earningsAug 4, 2026
DataMay 2025–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 5 wks
filed Aug 6, 2026
call held Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$720.06M
Trailing 12 months
Net income (TTM)
$109.07M
Trailing 12 months
Revenue growth YoY
+53.0%
Year over year
Operating margin
13.0%
Trailing 12 months
P / E (TTM)
19.6
Trailing earnings · reciprocal yield 5.1%
FCF yield
3.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+89.9%
Year over year · more shares
Price change (1Y)
+98.1%
Trailing year
Short interest
6.0%
Latest settlement · 2.7 days to cover
AI Brief
Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26
TL;DR. Hinge Health posted Q2 revenue of $213 million (53% YoY growth) and raised full-year 2026 revenue guidance to $856–$860 million alongside higher operating income guidance, while announcing a $105 million cash acquisition of Cylinder Health to enter GI care and a $300 million increase to its share repurchase authorization.
Bullish
- + Q2 revenue grew 53% YoY to $213 million, well above the $200–$202 million guidance range.
- + LTM calculated billings grew 52% YoY to $862 million, supporting continued revenue momentum.
- + Non-GAAP operating margin expanded to 29% from 19% a year ago and free cash flow tripled YoY to $100 million.
- + Yield is now expected to reach ~4.45% for the year, driving durable billings and revenue outperformance.
- + Migraine program launched within the quarter has gained 450+ clients covering more than 5 million lives.
- + Hinge Health signed a definitive agreement to acquire Cylinder Health for $105 million in cash to enter GI care.
Bearish
- − Cylinder Health acquisition will deploy $105 million in cash and bring near-term losses that must be integrated over the next year or two.
- − GAAP gross margin of 86% reflected benefit from a one-time tariff refund providing about 100 basis points of boost, which is not expected to repeat.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 16.4 · calm
Equity put/call 0.57
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+61%
above
Price vs 50-day avg
+11%
above
RSI (14)
62
neutral
MACD trend
Positive
52-week position
100%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+7%
trailing
6-month return
+177%
trailing
YTD return
+111%
this year
Relative strength
+164%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $88 › 200d $61 — 50d above 200d
Institutional flow
Accumulating
+37% holders QoQ · +105 funds added
Insider flow
Distributing
Net -$105.9K over 90 days · 100% sells
Short interest
Falling
5.99% of float · ▼ -11.2% MoM · 2.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
279 holders — near 1-yr high, broad support
Squeeze score
62
elevated · 0–100
Fundamentals
Revenue growth
+51%
Y/Y
Gross margin
80%
expanding
EPS growth
−783%
Y/Y
Free cash flow
$170.7M
Valuation
P/E 71.8
rich
Buyback
$496.5M
remaining
Quant / Vol
risk profile
Volatility
54%
annualized · 1-yr
Max drawdown
−42%
past year
ATR
4.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Q3 2026
Revenue
Initiated
$223M – $225M
prior qtr $212.82M
midpoint +5.3% QoQ
Non-GAAP income from operations
Non-GAAP
Initiated
$61M – $63M
Non-GAAP operating margin
Non-GAAP
Initiated
28%
Full Year 2026
Revenue
Initiated
$856M – $860M
prior FY $587.86M
midpoint +46.0% Y/Y
Non-GAAP income from operations
Non-GAAP
Initiated
$236M – $244M
Non-GAAP operating margin
Non-GAAP
Initiated
28%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+61%
Bullish
Price vs 50-day avg
+11%
Bullish
RSI (14)
62
Neutral
MACD trend
Positive
Bullish
52-week position
100%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $88 › 200d $61 — 50d above 200d
Institutional flow
Accumulating
+37% holders QoQ · +105 funds added
Insider flow
Distributing
Net -$105.9K over 90 days · 100% sells
Short interest
Falling
5.99% of float · ▼ -11.2% MoM · 2.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
279 holders — near 1-yr high, broad support
Price context
position in its 52-week range
Range low $31
Now $98 · 100%
Range high $98
vs 200-day avg +61%
vs 50-day avg +11%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free cash flow non-GAAP | $99.56M | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 101.41M
+0K Adjustment for employer taxes related to pre-IPO stock-based compensation
-1.85M Less purchases of property, equipment and software (including capitalized internal use software)
= Free cash flow 99.56M
|
|||
| Free cash flow margin non-GAAP | 47% | the three months ended June 30, 2026 filing | — |
| Non-GAAP gross margin non-GAAP | 87% | the three months ended June 30, 2026 filing | — |
| Non-GAAP gross profit non-GAAP | $185.35M | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP GAAP gross profit 183.95M
+1.13M Stock-based compensation expense
+45K Employer payroll tax expense related to stock-based compensation
+224K Amortization of intangible assets
= Non-GAAP gross profit 185.35M
|
|||
| Non-GAAP income from operations non-GAAP | $61.51M | the three months ended June 30, 2026 filing | — |
GAAP → non-GAAP reconciliationGAAP GAAP income (loss) from operations 40.44M
+19.09M Stock-based compensation expense
+1.32M Employer payroll tax expense related to stock-based compensation
+224K Amortization of intangible assets
+440K Acquisition-related expenses
= Non-GAAP income from operations 61.51M
|
|||
| Operating cash flow margin | 48% | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HNGE
this stock
Hinge Health, Inc.
|
$7.71B | +110.9% | +50.6% | 71.8 | 6.0% |
|
VEEV
Veeva Systems Inc
|
$45.44B | +26.3% | +28.1% | 45.9 | 3.1% |
|
TEM
Tempus AI, Inc.
|
$15.34B | +29.6% | +83.4% | — | 15.6% |
|
PMDIY
Pro Medicus Ltd./ADR
|
$12.20B | -29.7% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$11.02B | +52.9% | +28.2% | 33.8 | 5.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HNGE | +6.5% | +6.6% | +176.6% | +0.7% | +110.9% |
| SPY | -0.4% | -0.2% | +12.4% | +0.2% | +12.0% |
| vs SPY | +6.9% | +6.8% | +164.2% | +0.5% | +98.8% |
Capital returns
Buyback program
· as of Jul 29, 2026
Authorized
$496.50M
Spent (derived)
$0
Remaining
$496.50M
Spent
Remaining
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.